Caragol William J 4

What Happened
William J. Caragol, Chief Financial Officer of Mainz Biomed N.V. (MYNZ), was granted 290,000 restricted common shares on February 13, 2026. The reported transaction is an award/grant (code A) with a reported acquisition price of $0.00 (no cash consideration), consistent with a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-13; Form 4 filed: 2026-02-19 (filed six days after the transaction; likely outside the standard two-business-day reporting window).
• Security: Common shares granted as restricted shares under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan.
• Shares granted: 290,000; Reported acquisition price: $0.00 (no cash paid).
• Footnotes: (1) Grant under 2025 Omnibus Incentive Plan — no cash consideration. (2) Separately, 77,899 employee stock options were granted and previously reported on Form 3 (filed Jan 26, 2026).
• Shares owned after transaction: Not specified in the provided filing summary — see the full Form 4 for post-transaction holdings and any vesting schedule.

Context
This was a compensation-related grant of restricted shares (typically subject to vesting and other plan terms); such awards are common executive compensation and do not by themselves indicate an open-market bullish purchase or sale. For details on vesting, restrictions, and any subsequent disposition, consult the full Form 4 and the Omnibus Incentive Plan disclosures.